{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:52:58Z","timestamp":1793832778696,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021809","name":"Monash University Malaysia Jeffrey Cheah School of Medicine and Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.compbiomed.2025.109989","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:11:51Z","timestamp":1741295511000},"page":"109989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Exploring the potential of direct-acting antivirals against Chikungunya virus through structure-based drug repositioning and molecular dynamic simulations"],"prefix":"10.1016","volume":"189","author":[{"given":"Nida","family":"Kalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-307X","authenticated-orcid":false,"given":"Vinod RMT","family":"Balasubramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2025.109989_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41541-023-00722-x","article-title":"Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need","volume":"8","author":"Cherian","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.compbiomed.2025.109989_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009055","article-title":"Measuring the global burden of chikungunya and Zika viruses: a systematic review","volume":"15","author":"Puntasecca","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.compbiomed.2025.109989_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/v9120368","article-title":"Chikungunya virus: pathophysiology, mechanism, and modeling","volume":"9","author":"Ganesan","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.compbiomed.2025.109989_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-021-00778-8","article-title":"Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries","volume":"28","author":"Khongwichit","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.compbiomed.2025.109989_bib5","volume":"vol. 5","author":"Niranjan","year":"2019"},{"key":"10.1016\/j.compbiomed.2025.109989_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2023.2301573","article-title":"Ixchiq (VLA1553): the first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection","volume":"15","author":"Ly","year":"2024","journal-title":"Virulence"},{"key":"10.1016\/j.compbiomed.2025.109989_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib8","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1073\/pnas.1900656116","article-title":"Structural insights into RNA recognition by the Chikungunya virus nsP2 helicase","volume":"116","author":"Law","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.compbiomed.2025.109989_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J Transl Int Med"},{"key":"10.1016\/j.compbiomed.2025.109989_bib10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","article-title":"Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving","volume":"15","author":"Chhatwal","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib11","doi-asserted-by":"crossref","first-page":"8050","DOI":"10.3748\/wjg.v22.i35.8050","article-title":"Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12","volume":"22","author":"Werner","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib12","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jhep.2016.07.007","article-title":"Second generation direct-acting antivirals \u2013 do we expect major improvements?","volume":"65","author":"J.J. Feld","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/VOX as a hepatitis C virus infection salvage therapy in the real World: a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.compbiomed.2025.109989_bib14","first-page":"1","article-title":"The HCV treatment revolution continues: resistance considerations, pangenotypic efficacy, and advances in challenging populations","volume":"12","author":"Jacobson","year":"2016","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib15","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C: the clinical spectrum of disease","volume":"26","author":"Hoofnagle","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.compbiomed.2025.109989_bib16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4269\/ajtmh.13-0403","article-title":"Incubation periods of mosquito-borne viral infections: a systematic review","volume":"90","author":"Rudolph","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.compbiomed.2025.109989_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.compbiomed.2025.109989_bib18","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2025.109989_bib19","first-page":"452","article-title":"Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions","volume":"29","author":"Cooper","year":"2003","journal-title":"Pediatr. Nurs."},{"key":"10.1016\/j.compbiomed.2025.109989_bib20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.compbiomed.2025.109989_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126360","article-title":"A combination of doxycycline and ribavirin alleviated chikungunya infection","volume":"10","author":"Rothan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.compbiomed.2025.109989_bib22","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/infdis\/jiw358","article-title":"Chikungunya virus: in vitro response to combination therapy with ribavirin and interferon alfa 2a","volume":"214","author":"Gallegos","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.compbiomed.2025.109989_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhep.2015.09.024","article-title":"Daclatasvir plus SIM with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection","volume":"64","author":"Zeuzem","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiomed.2025.109989_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105446","article-title":"Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region","volume":"208","author":"Deng","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.compbiomed.2025.109989_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis","volume":"18","author":"Zoratti","year":"2020","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.compbiomed.2025.109989_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apsb.2015.09.008","article-title":"Direct anti-HCV agents","volume":"6","author":"Zhang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.compbiomed.2025.109989_bib28","doi-asserted-by":"crossref","DOI":"10.2217\/fvl-2019-0090","article-title":"In silico studies of fisetin and silymarin as novel chikungunya virus nonstructural proteins inhibitors","volume":"16","author":"Lani","year":"2021","journal-title":"Future Virol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/pathogens8030128","article-title":"Targeting the nsp2 cysteine protease of chikungunya virus using FDA approved library and selected cysteine protease inhibitors","volume":"8","author":"Kumar","year":"2019","journal-title":"Pathogens"},{"key":"10.1016\/j.compbiomed.2025.109989_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(01)00438-8","article-title":"Cysteine proteases of parasitic organisms","volume":"120","author":"Sajid","year":"2002","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.compbiomed.2025.109989_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12985-023-02271-0","article-title":"Repurposed drugs in combinations exert additive anti-chikungunya virus activity: an in-vitro study","volume":"21","author":"Davuluri","year":"2024","journal-title":"Virol. J."},{"key":"10.1016\/j.compbiomed.2025.109989_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acscentsci.0c01186","article-title":"SIM potently suppresses SARS-CoV-2 replication and synergizes with remdesivir","volume":"7","author":"Lo","year":"2021","journal-title":"ACS Cent. Sci."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525003403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525003403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:22:33Z","timestamp":1769275353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525003403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0010482525003403"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109989","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the potential of direct-acting antivirals against Chikungunya virus through structure-based drug repositioning and molecular dynamic simulations","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109989"}}